Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS])

Affiliations

¹ James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
² Movement Disorders Unit, Neurology Service, Internal Medicine Department, The Federal University of Minas Gerais, Belo Horizonte, Brazil.
³ The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York University Langone Health, New York, New York, USA.
⁴ Department of Molecular Medicine, Neurogenetics Research Centre, IRCCS Mondino Foundation, University of Pavia, Pavia, Italy.
⁵ School of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia.
⁶ The National Hospital, Queen Square and Reta Lila Weston Institute for Neurological Studies University College London, London, UK.

Alberto J Espay et al. Mov Disord. 2025 Aug.

. 2025 Aug;40(8):1744-1745.

doi: 10.1002/mds.30269. Epub 2025 Jun 27.

¹ James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
² Movement Disorders Unit, Neurology Service, Internal Medicine Department, The Federal University of Minas Gerais, Belo Horizonte, Brazil.
³ The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York University Langone Health, New York, New York, USA.
⁴ Department of Molecular Medicine, Neurogenetics Research Centre, IRCCS Mondino Foundation, University of Pavia, Pavia, Italy.
⁵ School of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia.
⁶ The National Hospital, Queen Square and Reta Lila Weston Institute for Neurological Studies University College London, London, UK.

No abstract available

References

1. Simuni T, Gochanour C, Nair AR, et al. Neuronal α‐synuclein disease stage progression over 5 years. Mov Disord 2025. 10.1002/mds.30191. - DOI - PMC - PubMed
1. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α‐synuclein disease: towards an integrated staging system for research. Lancet Neurol 2024;23:178–190. - PubMed
1. Chahine LM, Merchant K, Siderowf A, et al. Proposal for a biologic staging system of Parkinson's disease. J Parkinsons Dis 2023;13:297–309. - PMC - PubMed
1. Mollenhauer B, Dakna M, Kruse N, et al. Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression. Mov Disord 2020;35:1999–2008. - PMC - PubMed
1. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055–1061. - PMC - PubMed